Disease related to transplantation

This early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with the…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells…

This trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…

This study tests a new oral drug called revumenib in people with acute myeloid leukemia (AML) who have certain genetic changes. After a stem cell transplant, participants will take revumenib or a placebo to see if it helps keep the cancer from coming back. The trial involves 144 …

This study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…

This study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 wh…

This study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people w…

This early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug…

This phase 2 trial tests a combination of two oral drugs, ruxolitinib and belumosudil, for chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. cGvHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. T…

This study tests whether switching to belatacept (a drug) plus standard care can better treat early antibody-mediated rejection in kidney transplant patients compared to continuing standard care alone. About 290 adults with new donor-specific antibodies but no kidney function dec…

This study tests a drug called mezagitamab in people who have had a kidney transplant and are experiencing a type of rejection called antibody-mediated rejection (AMR). AMR happens when the body's immune system attacks the donor kidney, which can lead to kidney failure. The study…

This study tests whether giving fecal microbiota (from a healthy donor) via a tube or scope into the gut can safely help children and young adults with severe intestinal graft-versus-host disease that hasn't improved with steroids. About 20 participants aged 3 months to 25 years …

This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in people getting a stem cell transplant. About 438 adults at intermediate-to-high risk, as identified by a special model called daGOAT, will be enrolled. The goal is to…

This study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on…

This early-phase trial tests a new treatment called CK0802 for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant, where donor immune cells attack the patient's body. CK…

This phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well…

This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects an…

This early-phase trial is testing a combination of two drugs, loncastuximab tesirine and rituximab, as a first treatment for a rare blood cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ transplant. The study will first find the safe…

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …

This Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. …

This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…

This phase II trial tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body, causing serious symptoms. Axatilimab is…

This study tests whether injecting stem cells into the eye can help people with severe dry eye caused by graft-versus-host disease (GVHD), a complication of bone marrow transplants. The trial will include 30 adults who have not improved with standard treatments. Participants will…

This study will track 1000 people who receive a pancreas transplant to see if a special transport system (PancreasPak) helps the organ work better than standard methods. Researchers will compare rates of organ failure, hospital stay length, and survival up to one year after trans…

This early-phase study tests whether a single dose of specially grown regulatory T cells, combined with daily low-dose interleukin-2, can safely treat chronic graft-versus-host disease (cGvHD) in people whose condition did not improve with steroids or IL-2 alone. About 21 partici…

This study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition hasn't improved with steroids. The goal is to find a safe dose and see if it helps control the disease. Participants take th…

This early-phase trial tests whether adding vitamin C to standard steroid treatment helps people with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. About 35 participants aged 5 and older will receive vitamin C plus s…

This study tests whether a new drug called gecacitinib, combined with standard anti-rejection medicine, can prevent a serious complication called graft-versus-host disease (GVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The …

This early study tests a new medicine called TNX-1500 in 5 people who get a kidney transplant. The goal is to see if it is safe and can help prevent the body from rejecting the new kidney. Participants will be followed for one year to check for side effects and signs of rejection…

This study tested whether a person's own stem cells (mesenchymal stem cells) could help treat chronic active antibody-mediated rejection in kidney transplant recipients. Only 3 patients were enrolled before the study was stopped early due to serious side effects. The treatment di…

This pilot study tests whether an AI-based system can help doctors choose the right doses of immunosuppressant drugs for kidney transplant patients. The goal is to protect the new kidney from damage and rejection. The study will enroll 34 adults who have received a deceased donor…

This early-stage trial tests whether giving kidney transplant recipients a special treatment made from their donor's cells, combined with a light-based therapy called photopheresis, can safely reduce the risk of organ rejection. About 24 adults receiving their first kidney transp…

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This early-phase study tests whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) in children aged 8-18 who receive a stem cell transplant from a half-matched donor. GVHD occurs when donor cells attack the child's bod…

This early-phase study tests whether adding the drug venetoclax to standard transplant preparation is safe for people with chronic kidney disease and a blood cancer. Only 3 adults aged 18-70 will take part. The goal is to see if the combination helps the new stem cells and kidney…

This large international study looks for better ways to manage stem cell transplants in children and young adults with high-risk or relapsed acute lymphoblastic leukemia (ALL). The goal is to reduce serious complications and long-term side effects while keeping the transplant's p…

This study tests a new drug called VEL-101 in 120 kidney transplant patients. The goal is to see if VEL-101 can safely replace the standard drug tacrolimus, which often causes side effects. Researchers will monitor for rejection, side effects, and how the drug behaves in the body…

This phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…

This study tests a new drug called gecacitinib for people with acute graft-versus-host disease (GVHD) after a stem cell transplant. It is for those who did not get better or could not tolerate the usual second-line treatment. The trial will include 15 adults and aims to see if th…

This early study tests whether probiotics made from the patient's own or their donor's gut bacteria can improve intestinal health in people with acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten participants over age 50 will take probiotic capsules and be …

This phase 2 trial tests a combination of Gecacitinib (a pill) and a corticosteroid as the first treatment for grade II to IV acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The study will enroll 25 adults who have recently received a…

This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a radioactive antibody (131I-apamistamab) along with chemotherapy and low-dose radiation to prepare the bod…

This study will test a new blood test that looks for tiny molecules called miRNAs to detect HCMV infection earlier in people who have received a stem cell transplant. The standard DNA test can miss early signs, so researchers hope this new method will give doctors a head start. A…

This study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…

This study tests if adding sodium hyaluronate (a common moisturizer in artificial tears) to autologous serum eye drops provides better relief for moderate-to-severe dry eye disease. About 20 adults with dry eye from conditions like Sjögren's syndrome will use the new mix in one e…

This study looks at whether testing the liquid used to preserve donor livers and kidneys can predict infections in recipients. Researchers will check if bacteria or fungi in that fluid match infections that develop after transplant. The goal is to see if this simple test could he…

This early-stage study tests whether healthy volunteers can regularly take two natural gut supplements, propionate and butyrate, which are normally made by the body. The goal is to see if this approach is safe and practical before trying it in patients receiving donor stem cell t…

This study follows 250 patients receiving stem cell transplants to better understand engraftment syndrome, an early inflammatory complication. Researchers will track how different types of this syndrome relate to the risk of graft-versus-host disease and overall recovery. The goa…

This study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…

This study tests whether a short course of belimumab, a drug used for lupus, can improve detection of immune cells that cause transplant rejection. The goal is to help highly sensitized kidney transplant candidates—people whose immune systems are very picky about donor organs—get…

This study looks at blood samples from 1500 stem cell transplant patients to find markers that can predict chronic graft-versus-host disease (cGVHD), a serious complication. Researchers will use mass spectrometry to analyze proteins in the blood and combine this with patient data…

This study will follow 85 adults receiving stem cell transplants to track a serious but often missed complication called TA-TMA. Researchers want to find out how common it is and how it affects survival. Participants will provide blood samples and have standard follow-up care.

This study looks at why some people develop chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will collect blood, stool, saliva, and tissue samples from 75 participants to track immune cell changes over time. The goal is to better understand the d…

This study looks for early signs that a treatment called ECP is working in people who have had a lung transplant and developed chronic rejection (CLAD). Researchers will collect blood samples and, for some, lung MRI scans before, during, and after ECP therapy. The goal is to find…

This study will follow 4,000 people who had a stem cell transplant and later became critically ill, requiring intensive care. Researchers will collect information on their health, treatments, and survival. The goal is to learn more about what happens to these patients and how to …

This observational study at the University of Pittsburgh will enroll 24 kidney transplant recipients to deeply analyze why some rejections are stubborn. Researchers will use biopsies and blood samples to map immune cells and genetic changes. The goal is to better predict and unde…

This early-phase study investigates whether the opioid system is involved in placebo effects on both physical pain and the pain of social rejection. Sixty adults who recently experienced an unwanted breakup will receive either naloxone (which blocks opioids) or saline, and be tol…

This study aims to find biological markers (biomarkers) in blood, tears, and eye cells from 110 adults with seven rare eye diseases. Researchers will compare these markers between patients and healthy controls to see if they differ and if they relate to disease symptoms. The goal…

This study follows 600 kidney transplant patients to see if a blood test (TruGraf and TRAC) can help doctors manage immunosuppression and detect early signs of rejection. The goal is to improve long-term outcomes by reducing the need for invasive biopsies. Participants will be mo…

This study will use advanced MRI scans to look at kidney transplants in 140 patients. The goal is to see if MRI can measure how well the kidney is working and tell the difference between stable function and problems like rejection. Researchers hope this could lead to a non-invasi…

This study will analyze the DNA and chemical marks on DNA of 200 children who have had a liver or kidney transplant. Researchers want to find genetic clues that might explain why some children develop serious complications like organ rejection, infections, or cancer after transpl…